Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-TL1A synbody
- Development stage
- Preclinical
- Lead developer
- SAGEbio
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
SAGEbio's lead program is an anti-TL1A synbody, a modular biologic engineered as a single-domain synthetic antibody. Developed using AI-guided sequence design and an in-house single-domain antibody library, this therapeutic is designed to selectively block the interaction between Tumor Necrosis Factor-like Ligand 1A (TL1A) and its receptor, Death Receptor 3 (DR3). TL1A is a key mediator and amplifier of chronic inflammation and fibrosis. By inhibiting the TL1A:DR3 axis, the synbody aims to treat inflammatory bowel disease (IBD) and fibrotic diseases while potentially preserving broader immune function. The drug is currently in preclinical development.
- Other names
- single-domain synthetic antibodymodular biologicsynbody
02
Targets
Beyond the preview
Go deeper on anti-TL1A synbody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-TL1A synbody.